Innovent Biologics and Daiichi Sankyo have entered an exclusive agreement to commercialize the FLT3 inhibitor Vanflyta in China for FLT3-ITD-positive leukemia patients. #Biotech #Pharma #Oncology #AML #Healthcare #LifeSciences #DaiichiSankyo Not financial advice. For educational purposes only.